---
title: Blood biomarkers in Alzheimer's disease
date: '2021-11-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/34752348/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Zkrxt7ktlCbHBXEV3v65xxSnkSWNsJ1A6Fq3gBniKhGfIUslK&fc=20210907212339&ff=20211112194353&v=2.15.0
source: metablomics[MeSH Terms]
description: 'CONCLUSIONS: Blood biomarkers are more cost- and time-effective than
  CSF biomarkers. However, immediate applicability in clinical practice is relatively
  unlikely. The main limitations come from the difficulty of measuring and standardising
  thresholds between different laboratories and the failure to replicate results.
  Of all the molecules studied, apoptosis and neurodegeneration biomarkers and the
  biomarker panels obtained through "omics" approaches, such as isolated or combined
  ...'
---
CONCLUSIONS: Blood biomarkers are more cost- and time-effective than CSF biomarkers. However, immediate applicability in clinical practice is relatively unlikely. The main limitations come from the difficulty of measuring and standardising thresholds between different laboratories and the failure to replicate results. Of all the molecules studied, apoptosis and neurodegeneration biomarkers and the biomarker panels obtained through "omics" approaches, such as isolated or combined ...